VXRT - Vaxart acquires second GMP manufacturing facility

Vaxart (NASDAQ:VXRT) has announced the acquisition of its second GMP manufacturing facility. The clinical-stage biotechnology company entered into an agreement with Kindred Bioscience for the purchase of KindredBio's manufacturing equipment and sublease of its GMP manufacturing plant in Burlingame, California. Shares are down 2.76% pre-market despite the news The Burlingame facility, along with Vaxart's existing GMP manufacturing facility in South San Francisco, will develop materials for the company's COVID-19 and norovirus oral vaccine tablets. The site can produce biologic drug substances at up to 500L bioreactor scale. Vaxart expects the facility to be operational for GMP production in Q122. The firm recently began a Phase II trial of its COVID-19 vaccine candidate and has several Phase I studies of its norovirus vaccine candidate underway.

For further details see:

Vaxart acquires second GMP manufacturing facility